Prakt. lékáren. 2013; 9(3): 120-123

Fundamentals of prevention and treatment of kidney diseases

Romana Ryšavá
Klinika nefrologie 1. LF UK a VFN Praha

Chronic kidney diseases affect nearly a tenth of our population and are becoming not only a medical issue, but also a social-economic

problem. The best measures taken to prevent the development of advanced stages of disease include the implementation of screening

programs to find patients with an existing renal injury or those at a high risk. Basic tests include measurement of serum creatinine

and glomerular filtration rate, urine sediment analysis and proteinuria or microalbuminuria testing. Measures that can significantly

slow down (or even stop) the progression of chronic nephropathies are treatment with angiotensin-converting enzyme inhibitors or

angiotensin II AT1 receptor antagonists, consistent hypertension management with achievement of normotension (< 140/90 mmHg),

and reduction of proteinuria below 0.5 g/day. Additional measures, such as reducing dietary protein intake, treatment of dyslipidemia,

no smoking, weight reduction, or effective glycemic control in diabetics, may also significantly contribute to reducing the risk of

developing kidney disease.

Keywords: chronic kidney disease, microalbuminuria, proteinuria, glomerular filtration rate, low-protein diet

Published: July 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ryšavá R. Fundamentals of prevention and treatment of kidney diseases. Praktické lékárenství. 2013;9(3):120-123.
Download citation

References

  1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1.
  2. Rychlík I, Nehézová K. Epidemiologie chronického onemocnění ledvin. Pokroky v oboru nefrologie 2009; 3(1): 4-10.
  3. Tesař V. Renální riziko, koncept a kalkulace individuálního rizika. Pokroky v oboru nefrologie 2009; 3(1): 11-20.
  4. Hsu C-Y, Ordonez JD, Chertow GM, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 2008; 73: 101-107. Go to original source... Go to PubMed...
  5. Doporučení České nefrologické společnosti a České společnosti klinické biochemie ČLS JEP k vyšetření glomerulární filtrace. Aktuality v nefrologii 2009; 15: 129-139.
  6. Verhave JC, Gansevoort RT, Hillege HL, et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kideny Int 2004; 66(Supll. 92): S18-21. PREVEND Study. Go to original source... Go to PubMed...
  7. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaboratiive meta-analysis. Lancet 2010; 375(9731): 2073-2081. Go to original source... Go to PubMed...
  8. Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? Ann Clin Biochem 2009; 46: 205-217. Go to original source... Go to PubMed...
  9. Brancati FL, Whelton PK, Randall BL, et al. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA. 1997; 278(23): 2069-2074. Go to original source...
  10. Monhart V. Hypertenze a renální riziko. Pokroky v oboru nefrologie 2009; 3(1): 21-26.
  11. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869. Go to original source... Go to PubMed...
  12. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotenzin-II receptor blocker and angiotenzin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-124. Go to original source... Go to PubMed...
  13. Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, deChamplain J, Weber MA and Raz I. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE study. Kidney Int 2007; 72: 879-885. Go to original source... Go to PubMed...
  14. Baigent C, Landray MJ, Reith C, et al.on behalf of the SHARP investigators. The effect of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192. Go to original source... Go to PubMed...
  15. Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. AJKD 2009; 54: 647-662. Go to original source... Go to PubMed...
  16. Teplan V. Chronická renální insuficience a selhání ledvin. In: Teplan: Nefrologie. V. díl edice Vnitřní lékařství. Triton 2003, Praha. pp. 133-139.




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.